BMS/Pfizer deal accelerates Portola's anticoagulation antidote
This article was originally published in Scrip
Bristol-Myers Squibb and Pfizer have signed a clinical collaboration agreement with Portola to conduct a proof-of-concept study investigating Portola's universal Factor Xa inhibitor antidote, PRT4445, with a view to accelerating the development of the drug as a potential antidote to BMS/Pfizer's oral Factor Xa inhibitor, Eliquis (apixaban).
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.